Titomic Secures Early Manufacturing Development Contract with Leading Defense Prime
HUNTSVILLE, Ala., Dec. 15, 2025 /PRNewswire/ -- Titomic Limited (ASX: TTT), a…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
